Common Stock, par value $0.0001 per share
- Symbol
- VANI
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Quarterly Report · 10-Q
Vivani Medical, Inc.
VANINASDAQEQUITYCurrent
Quarterly Report
Company context
Leveraging its proprietary NanoPortal™ platform, Vivani develops miniature, biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence and improving patient tolerance to their medication. Vivani is developing a portfolio of GLP-1 based implants for metabolic diseases including obesity and type 2 diabetes. These NanoPortal implants are designed for once- or twice-yearly administration to provide patients with the opportunity to realize the full potential benefit of their medication by avoiding the numerous challenges associated with the daily or weekly administration of orals and injectables, including tolerability issues and loss of efficacy. Medication non-adherence occurs when patients do not take their medication as prescribed. This affects an alarming number of patients, approximately 50%, including those taking daily pills. For more information, please visit: www.vivani.com.
Current securities
Historical securities (6)
EYESNASDAQ · EQUITY · Historical · closed Aug 30, 2022EYESNASDAQ · EQUITY · Historical · closed Aug 30, 2022EYESNASDAQ · ETF · Historical · closed Oct 22, 2026EYESWNASDAQ · WARRANT · Historical · closed Aug 30, 2022VANIWOTC · WARRANT · Historical · closed Mar 13, 2024VANIWOTC · WARRANT · Historical · closed Mar 13, 2024
Registered securities in this filing
Vivani Medical, Inc. · 10-Q · Filed 2026-08-13
As-filed source
As filedOpen full document ↗